DexCom, Inc. (NASDAQ:DXCM) Stock Position Increased by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans grew its position in DexCom, Inc. (NASDAQ:DXCM) by 44.2% in the 3rd quarter, Holdings Channel.com reports. The firm owned 314,102 shares of the medical device company’s stock after buying an additional 96,274 shares during the period. Thrivent Financial for Lutherans’ holdings in DexCom were worth $21,058,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in DXCM. Legal & General Group Plc grew its holdings in shares of DexCom by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after acquiring an additional 49,076 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of DexCom by 16.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after acquiring an additional 353,019 shares during the last quarter. 1832 Asset Management L.P. raised its position in shares of DexCom by 1.1% in the first quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company’s stock valued at $252,906,000 after purchasing an additional 20,400 shares during the period. Vaughan Nelson Investment Management L.P. boosted its holdings in DexCom by 14.4% during the second quarter. Vaughan Nelson Investment Management L.P. now owns 1,617,001 shares of the medical device company’s stock valued at $183,336,000 after acquiring an additional 203,043 shares during the period. Finally, Rathbones Group PLC boosted its stake in DexCom by 5.8% during the 2nd quarter. Rathbones Group PLC now owns 1,401,802 shares of the medical device company’s stock valued at $158,936,000 after purchasing an additional 76,727 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

DexCom stock opened at $75.24 on Thursday. The business has a 50 day moving average of $70.29 and a 200-day moving average of $90.44. The company has a market capitalization of $29.39 billion, a P/E ratio of 45.05, a P/E/G ratio of 2.33 and a beta of 1.17. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This trade represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. increased their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Oppenheimer reduced their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Robert W. Baird raised their price objective on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. Piper Sandler reissued an “overweight” rating and set a $90.00 price objective on shares of DexCom in a research report on Monday, August 26th. Finally, Stifel Nicolaus upped their price target on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.